Novartis to settle China bribe case for US$25m
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
Hong Kong
NOVARTIS AG agreed to pay US$25 million to settle a US Securities and Exchange Commission case that claimed the Swiss drugmaker violated the Foreign Corrupt Practices Act by paying bribes to health professionals in China to increase sales from 2009 to 2013.
The SEC issued a cease-and-desist order late on Wednesday saying Novartis submitted a settlement offer and the agency has accepted it. The company's payment includes US$2 million in a civil penalty and US$1.47 million in interest, according to the order posted on the SEC's website. Novartis didn't admit or deny the SEC's claims.
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
20 photos that show how dramatically Singapore has changed in two decades
Singapore’s key exports up 15.3% in March from electronics surge, exceeding forecasts
